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proteases, toxic oxygen metabolites, nitric oxide, and phospholipases. Human neutrophil peptides (HNP), also known as ␣-defensins, are another major product of activated and deteriorating neutrophils. These 3.5-kDa, 29-to 35-amino acid cationic peptides are cysteine rich and have a ␤-sheet structural conformation (9) . HNP types 1-4 are abundant in human neutrophils, constituting 5% of all neutrophil proteins and 30-50% of the total protein content of the azurophilic granules (20) . Although they lack enzymatic activity, they possess a wide range of antimicrobial and cytotoxic capabilities. Whereas antimicrobial activity primarily takes place in neutrophil vacuoles after phagocytosis, activated human neutrophils also release up to 10% of their defensin content extracellularly (8) .
␣ 1 -AT is a serine protease inhibitor with potent anti-inflammatory properties. Its major function is thought to be inhibition of the deleterious effects of neutrophil proteases, particularly those associated with neutrophil elastase. ␣ 1 -AT deficiency was chosen as a model to investigate organ-specific and unopposed effects of HNP because it has also been shown that, in vitro, ␣ 1 -AT binds to HNP molecules and neutralizes their cytotoxic effects on bronchial epithelial cells (17, 22) . A relative imbalance of ␣ 1 -AT and proteases (in favor of an increased burden of proteases) has been demonstrated in other neutrophil-mediated lung diseases such as cystic fibrosis (4) and emphysema not related to congenital ␣ 1 -AT deficiency (7, 23) , suggesting that ␣ 1 -AT plays a critical role in modulating the effects of HNP and neutrophil products in a number of inflammatory lung diseases. In this context, the presence of adequate local concentrations of ␣ 1 -AT may be critical for the maintenance of lower respiratory tract homeostasis, particularly in the presence of neutrophils releasing toxic factors.
In this study, we evaluated the cytotoxic and inflammatory activities of HNP in ␣ 1 -AT-deficient individuals with mild pulmonary function impairment. We demonstrate that lower respiratory tract HNP levels are significantly increased in ␣ 1 -AT-deficient patients compared with healthy subjects and that HNP are cytotoxic to alveolar macrophages at concentrations similar to those measured in the airways of a small number of ␣ 1 -AT-deficient individuals. HNP also stimulate alveolar macrophages to release the potent neutrophil chemoattractants leukotriene B 4 (LTB 4 ) and interleukin-8 (IL-8). Our studies suggest that HNP-mediated chemoattractant production contributes to the chronic neutrophil burden in the lower respiratory tract that is characteristic of ␣ 1 -AT-deficient individuals with lung function impairment. HNP appear to be important neutrophil-derived factors with the capacity to injure lung tissue and amplify the inflammatory response in the absence of adequate levels of ␣ 1 -AT. These findings are likely relevant to systemic neutrophil-mediated inflammatory processes as well as localized inflammation in other organ systems.
METHODS

Subjects.
A total of 33 ␣1-AT-deficient individuals (16 men and 17 women, 46 Ϯ 2 yr of age) were studied at the University of Florida and the National Institutes of Health Clinical Center as part of institutional review board-approved protocols. Informed consent was obtained from all participants. Homozygous Z-type ␣ 1-AT deficiency occurred in 32 individuals, and the remaining individual carried the at-risk phenotype PI ‫ء‬ ZM Malton. The patients had mild lung disease, with an average forced expiratory volume in 1 s (FEV1) of 87 Ϯ 4%, forced vital capacity of 100 Ϯ 4%, and diffusion capacity of 97 Ϯ 5% of predicted values. Thirteen individuals (39%) met criteria for obstructive lung disease by FEV 1 criteria (Ͻ80% of predicted). None were smokers at the time of study. Twelve individuals were exsmokers; time since cessation was 0.8-38 yr. Despite their normal lung function indexes, the majority of subjects had emphysematous changes on chest CT. In the few patients receiving it, intravenous ␣ 1-AT augmentation therapy was discontinued Ն3 wk before participation in the study. The mean baseline serum ␣1-AT level of 6.2 Ϯ 2.2 M confirmed the clearance of previously administered exogenous protein. Six subjects were using inhaled steroids at the time of study entry. All subjects were at their baseline state of health at the time of bronchoscopy, without clinical signs of pulmonary infection, exacerbation of chronic obstructive lung disease, or uncontrolled asthma. As a control population, we studied 21 healthy nonsmoking individuals without ␣ 1-AT deficiency (14 men and 7 women, 37 Ϯ 3 yr of age). These individuals had a mean serum ␣1-AT level of 28.1 Ϯ 1.1 M and normal lung function (102 Ϯ 4% of predicted FEV1). ␣1-AT protease inhibitor types were determined by isoelectric focusing of the serum, and serum ␣1-AT levels were determined by nephelometry (Behring Diagnostics, Marburg, Germany) using a purified ␣ 1-AT standard (5) .
Subjects underwent pulmonary function testing within 2 days before bronchoscopy. Spirometry was performed and evaluated according to American Thoracic Society standards (1) .
Bronchoalveolar lavage and fluid processing. Bronchoalveolar lavage (BAL) was performed on all study subjects. Briefly, after local anesthesia with lidocaine, a fiber-optic bronchoscope was wedged in the right middle lobe or lingula using direct visualization, and five 20-ml aliquots of sterile saline solution were injected and immediately recovered by gentle suction. The BAL fluid was filtered through surgical gauze to remove mucus plugs and cellular debris. After filtration, an aliquot of fluid from each lobe was removed for cell counts and cytoslide preparation. Cell counts were performed using a hemocytometer, cytospots were prepared using a Cytospin II (Shandon Instruments, Cheshire, UK), and differential cell counts were performed by light microscopy after treatment with Diff-Quik stain solutions (Allegiance, McGraw Park, IL). The remaining BAL fluid was centrifuged at 300 g for 15 min at 4°C. The supernatant was removed and stored at Ϫ70°C until protein quantification assays were performed. Cell pellets were resuspended in serum-free RPMI 1640 culture medium with penicillin (250 U/ml) and streptomycin (250 U/ml, RPMI ϩ P/S; Biofluid, Rockville, MD). Cell viability was calculated before and immediately after each experiment by trypan blue exclusion. Because recovered BAL fluid consists of the instilled saline in addition to the cellular and soluble components of the lower respiratory tract epithelial lining fluid (ELF), quantitative assessment of HNP and other soluble markers of inflammation, as well as intersubject comparison, is complicated by variable dilution of the ELF. As a molecule that is freely diffusible between the ELF and plasma, urea is used as an intra-alveolar marker to determine the degree of ELF dilution. If it is assumed that the plasma urea concentration is approximately equal to the ELF concentration (19) , measurement of urea in plasma and BAL fluid allowed calculation of the ELF volume obtained in each BAL, and all BAL measurements are expressed as ELF concentrations.
Determination of BAL HNP concentration. HNP concentration in BAL fluid was determined using a slight modification of a previously described enzyme-linked immunoassay (18) . Immulon-2 plates (Dynatech, Chantilly, VA) were coated overnight at room temperature with mouse anti-HNP monoclonal antibody (Bachem, Torrance, CA) suspended in 0.1 M carbonate buffer, pH 9.6. The plates were washed four times in PBS-Tween and blocked with 1% gelatin in 20 mM Tris⅐HCl and 500 mM NaCl, pH 7.5 (TBS), for 1 h at room temperature. A standard curve was prepared using synthesized HNP (Bachem) diluted in TBS ϩ 0.01% hexadecyltrimethylammonium bromide (CETAB; Fluka Chemical, Milwaukee, WI). The samples were applied directly to the Immulon plates, and end-point 1:2 dilutions were performed using TBS ϩ CETAB diluent. After 2 h of incubation, the plates were washed as described above. Polyclonal rabbit anti-HNP antiserum (Domcroft, Lovettsville, VA) diluted 1:500 in TBS and CETAB was added to the wells and incubated for 1.5 h. After they were washed, the plates were incubated for 1 h in goat anti-rabbit IgG horseradish peroxidase-conjugated antibody (Boehringer Mannheim Biochemicals, Indianapolis, IN) diluted 1:1,000 in TBS ϩ 1% gelatin. The plates were developed by addition of 100 l of O-phenylenediamine (Sigma, St. Louis, MO), 0.2 mg/ml in 20 mM citrate buffer, pH 4.7, containing 30% H 2O2 (0.25 g/ml). The reaction was stopped by the addition of 2.5 N H2SO4, and the plates were read at 492 nm using a SPECTRAmax plate reader (Molecular Devices, Sunnyvale, CA). Sample concentrations were calculated using best-of-fit curve of the standards, and values were corrected for BAL fluid dilution to give ELF concentration of HNP. This ELISA has an interassay reproducibility of Ͼ95% and was sensitive to 0.78 nM HNP.
Issues specific to the quantification of HNP in biological specimens include cationicity and the tendency of the peptides to form dimers. The high cationicity of HNP can affect the sensitivity of ELISA by nonspecific binding to plastics, for example, and is partially mitigated by the use of the detergent CETAB. The tendency of HNP to form dimers can also alter the measured levels in BAL fluid, but the use of a polyclonal and a monoclonal antibody in the sandwich immunoassay likely offers sufficiently broad specificity for accurate quantification. To address these issues, additional methods were utilized as confirmation of BAL ELISA analysis.
Identification of HNP by HPLC and Western blot analysis. The presence of HNP in BAL fluid, previously determined by ELISA, was confirmed by reverse-phase HPLC and Western blotting. BAL fluid obtained from an ␣1-AT-deficient individual and from a healthy control subject was concentrated by evaporation under nitrogen. Reverse-phase HPLC analysis was performed using a Hewlett Packard 1100 chromatograph (Waldbronn, Germany). BAL concentrate was equilibrated with 0.1% trifluoroacetic acid (TFA)-acidified water and injected into an HPLC column (Zorbax SBC-8). HNP were separated from other BAL proteins by gradient elution in 100% buffer (0.1% TFA-H2O) to 50% buffer (0.85% TFA-acetonitrile) over 45 min. Fractions were collected every 5 min, evaporated under nitrogen, reconstituted in tricine-SDS sample buffer, and electrophoresed through a 4-20% tricine-SDS gel. Proteins were transferred to a nitrocellulose membrane (Novex, San Diego, CA) at 22 V for 2 h in transfer buffer (12 mM Tris-base and 96 mM glycine in 20% methanol, pH 8.3).
After transfer, the nitrocellulose sheet was washed in phosphatebuffered saline (PBS), pH 7.4 (GIBCO BRL, Grand Island, NY), containing 0.05% polyoxyethylenesorbitan monolaurate-Tween 20 (Sigma) and blocked overnight in 1% blocking buffer (Tropix, Bedford, MA) in PBS-0.3% Tween. The membrane was incubated for 2 h with rabbit polyclonal anti-HNP antibody (Bachem) diluted 1:1,000 in blocking buffer. After it was washed in PBS-0.3% Tween, the membrane was incubated for 1 h with horseradish peroxidase-conjugated goat anti-rabbit IgG (Boehringer Mannheim) diluted 1:1,000 in blocking buffer. Binding of the secondary antibody was detected using a chemiluminescence detection system (Amersham, Arlington Heights, IL).
Quantitation of antiprotease and inflammatory markers in BAL fluid and cell culture supernatants. Quantitative measurements of ␣ 1-AT and neutrophil elastase were performed using indirect sandwich immunoassay. IL-8 levels were measured by commercial quantitative sandwich ELISA (R & D Systems, Minneapolis, MN) according to the manufacturer's instructions using a SPECTRAmax plate reader and SoftmaxPRO software (Molecular Devices).
Before determination of LTB 4 concentrations, potentially crossreacting material was removed by extraction of eicosanoids with C18 Sep-Pak cartridges (Waters, Milford, MA) as previously described (12) . Briefly, samples were treated with ethanol and centrifuged at 375 g for 10 min to remove cellular debris. Samples were acidified and applied to the cartridges at a rate of 0.5 ml/min using a vacuum manifold. The columns were washed with distilled water, 10% ethanol, and petroleum ether before elution of the eicosanoids with methyl formate (Sigma). The methyl formate was dried under a continuous stream of nitrogen gas. After extraction of eicosanoids from the supernatants, the sample was resuspended in assay buffer, and LTB4 was measured by an enzyme immunoassay kit (Perspective Biosystems, Framingham, MA). The efficiency of extraction was assessed by addition of tritiated LTB4 to the medium, and the results were corrected for the extraction efficiency.
Cell culture. Alveolar macrophages obtained from normal subjects and ␣1-AT-deficient individuals were utilized to evaluate LTB4 and IL-8 responses after exposure to HNP at concentrations approximating those measured in the lower respiratory tract. To isolate alveolar macrophages, BAL fluid cell pellets were resuspended in RPMI ϩ P/S at 1.0 ϫ 10 6 viable macrophages/ml and plated in duplicate in tissue culture plates (Costar, Cambridge, MA). Cells were incubated for 2 h at 37°C in the presence of 5% CO2 to allow macrophage adherence and then washed three times with RPMI ϩ P/S. The resulting alveolar macrophage population was Ͼ95% viable by trypan blue exclusion. Cells were cultured at 37°C in 5% CO2 in the presence of increasing concentrations of HNP (125, 500, 1,625, and 2,500 nM). To study possible interactions between HNP and neutrophil elastase on LTB4 and IL-8 release from alveolar macrophages, we cultured the cells in the presence of HNP and neutrophil elastase (Athens Research and Technology, Athens, GA). To study possible modulation of alveolar macrophage chemoattractant production by ␣1-AT, we cultured cells in the presence of the average concentration of ␣1-AT (Athens Research and Technology) detected in the ELF of normal individuals (2,200 nM). Aliquots were removed at interval time points and centrifuged at 3,000 g for 5 min, and the supernatants were frozen at Ϫ20°C for 3 h and then stored at Ϫ70°C until assayed for LTB4 or IL-8 production. As controls we used alveolar macrophages incubated in medium alone or medium plus neutrophil elastase or ␣1-AT incubated in the absence of alveolar macrophages for the same period and in the same conditions and processed identically.
Cell viability evaluated after each experiment did not differ between culture conditions. Because of the high number of cells required for this experiment, these analyses were performed in a limited number of subjects (6 healthy controls and 7 ␣1-AT-deficient individuals).
Cytotoxicity assay. HNP-mediated human alveolar macrophage cytotoxicity was studied with a chromium release assay. Alveolar macrophages obtained from ␣ 1-AT-deficient individuals (n ϭ 5) and control subjects (n ϭ 4) were resuspended at 2 ϫ 10 6 cells/ml in RPMI ϩ P/S containing 0.5 mCi of 51 Cr (NEN Dupont, Boston, MA) for 1 h at 37°C in 5% CO2. The unincorporated 51 Cr was removed from the cells by three washes in RPMI. Cells (2 ϫ 10 4 /well) were then incubated at 37°C in 5% CO2 with serial dilutions of HNP (3,500-28,000 nM). Cells in medium alone and cells lysed with Triton X-100 (Research Products International, Delta Lane, IL) were used to calculate spontaneous and maximum 51 Cr release, respectively. After an 18-h incubation, 51 Cr in the supernatant was measured using a gamma counter (Titertek, Huntsville, AL), and the percent lysis was calculated by the following equation: (cpmexptl Ϫ cpmspont)/ (cpmmax Ϫ cpmspont) ϫ 100, where cpmexptl, cpmspont, and cpmmax represent experimental, spontaneous, and maximal counts per minute, respectively. All conditions were repeated in triplicate.
Statistical evaluation. Values are means Ϯ SE. Control and subject ELF values were evaluated using unpaired t-test or a Mann-Whitney rank test if data were found to deviate from a Gaussian distribution by the Kolmogorov-Smirnov test. Comparisons of alveolar macrophage LTB 4 and IL-8 production from normal and ␣1-AT-deficient individuals were determined using a Mann-Whitney rank test. Wilcoxon's rank test was used for intragroup comparisons. Correlation coefficients were determined using Spearman's rank test. All tests were performed using the statistics programs Prism 3.0 (Graphpad Software) or StatView 5.0 (SAS Institute).
RESULTS
HNP levels in the lower respiratory tract. HNP were demonstrated in the BAL fluid of ␣ 1 -AT-deficient individuals by reverse-phase HPLC, Western blot analysis, and immunoassay. Although no peaks of protein were noted over 15-20 min of elution of concentrated BAL fluid in a normal individual, an ␣ 1 -AT-deficient individual with increased ELF neutrophils demonstrated a peak at 18-20 min of elution, which corresponds to a similar peak when normal BAL fluid was spiked with synthesized HNP types 1 and 2 ( Fig. 1, A-C) . The amplitude of the peak detected in the ␣ 1 -AT-deficient individual's BAL fluid was specifically increased by the addition of synthesized HNP types 1 and 2 (Fig. 1D) . Western blot analysis of the 15-20 elution time-pooled fractions from the ␣ 1 -AT-deficient individual (Fig. 1, inset, lane 2) demonstrated an immunoreactive 4-kDa protein similar to synthesized HNP types 1 and 2 in lane 1 and partially purified neutrophil extract in lane 4. This observation contrasts with the lack of an immunoreactive 4-kDa band in lane 3, representing a similar pooled fraction from a normal BAL fluid sample (Fig. 1, inset) . The mean ELF concentration of HNP as determined by ELISA was 68-fold greater in ␣ 1 -AT-deficient individuals than in healthy control subjects (1,976 Ϯ 692 vs. 29 Ϯ 12 nM, P Ͻ 0.0001; Fig. 2) .
The mean percentage of neutrophils in the BAL fluid was significantly higher in ␣ 1 -AT-deficient individuals than in healthy controls (10.1 Ϯ 2.7 vs. 1.0 Ϯ 0.1, P ϭ 0.0099). Consistent with this higher burden of neutrophils in the lower airways, neutrophil elastase levels were also higher in ␣ 1 -ATdeficient individuals (192.5 Ϯ 71.70 vs. 12.90 Ϯ 5.500 nM, P ϭ 0.05). Lower respiratory tract HNP levels significantly correlated with the degree of neutrophil burden as expressed by the percentage of BAL neutrophils and the ELF neutrophil concentration, as well as neutrophil elastase levels (Table 1) .
HNP-mediated cytotoxicity.
A 51 Cr release assay was used to determine the cytotoxic effect of HNP on alveolar macrophages from healthy control (n ϭ 4) and ␣ 1 -AT-deficient individuals (n ϭ 5). This demonstrated cellular cytotoxicity proportional to the amount of HNP in the medium over a wide range of concentrations (Fig. 3 ). There were no significant differences in the cytotoxic effect of HNP on alveolar macrophages from normal or ␣ 1 -AT-deficient individuals. Extrapolation of the in vitro cytotoxicity assay findings to in vivo circumstances revealed that only 6 of the 33 ␣ 1 -AT-deficient individuals and none of the healthy control subjects had HNP ELF concentrations that induced cytotoxicity in alveolar macrophages under the assay conditions. In this context, exposure of alveolar macrophages to the average ELF concentration of HNP among ␣ 1 -AT-deficient individuals (1,976 Ϯ 692 nM) would result in cytotoxicity in Ͻ5% of the cells.
Dose-response effect of HNP on alveolar macrophage chemoattractant production. Alveolar macrophages harvested from healthy subjects and ␣ 1 -AT-deficient individuals incubated with increasing concentrations of HNP demonstrated a proportional increase in LTB 4 production (Fig. 4) . At 24 h, Fig. 3 . Cytotoxicity in alveolar macrophages from healthy control subjects (s, n ϭ 4) and ␣1-AT-deficient individuals (F, n ϭ 5) after 24 h of incubation with 3,500, 7,000, 14,000, and 28,000 nM HNP. Values (means Ϯ SE) are expressed as 51 Cr-labeled sodium chromate detected in supernatant as percentage of total cellular 51 Cr-labeled sodium chromate released after treatment with Triton X-100.
there was a significant increase in LTB 4 production by alveolar macrophages from control subjects and ␣ 1 -AT-deficient individuals incubated with 2,500 nM HNP (a concentration of HNP at the level of detectable HNP-induced alveolar macrophage cytotoxicity). Although alveolar macrophages from ␣ 1 -AT-deficient individuals exposed to 2,500 nM HNP tended to produce more LTB 4 at 1 and at 24 h than control subjects, this difference was not significant for the separate groups.
Production of IL-8 increased in alveolar macrophages from ␣ 1 -AT-deficient individuals 24 h after incubation with HNP (Fig. 5) . Production of IL-8 at baseline and after incubation with increasing doses of HNP was consistently two to four times greater in alveolar macrophages from normal subjects than in those from deficient individuals (data not shown).
Effect of neutrophil elastase and ␣ 1 -AT on HNP-induced chemoattractant production. To evaluate the effect of HNP on alveolar macrophage production of LTB 4 in the typical in vivo milieu of ␣ 1 -AT-deficient individuals, alveolar macrophages isolated from healthy control and ␣ 1 -AT-deficient individuals were studied using neutrophil elastase and HNP concentrations approximating the observed levels in the ELF of ␣ 1 -AT-deficient individuals (220 and 1,625 nM, respectively). The modulating effect of ␣ 1 -AT was evaluated using concentrations approximating the mean ELF level observed in healthy control subjects (2,200 nM). Fig. 4 . Dose-response relation between HNP concentration and LTB4 production by alveolar macrophages from healthy control subjects (A, n ϭ 6) and ␣1-AT-deficient individuals (B, n ϭ 7) incubated for 24 h without (control) and with 125, 500, and 2,500 nM HNP. Values are means Ϯ SE. *P Ͻ 0.05 compared with control (unpaired t-test). Consistent with the dose-response experiments, HNP alone significantly increased LTB 4 and IL-8 production over baseline in alveolar macrophages isolated from ␣ 1 -AT-deficient individuals after 24 h of incubation. Neutrophil elastase alone did not significantly increase LTB 4 or IL-8 production in alveolar macrophages isolated from ␣ 1 -AT-deficient individuals but significantly increased LTB 4 in normal alveolar macrophages (data not shown). The addition of HNP plus neutrophil elastase significantly increased LTB 4 production over baseline in ␣ 1 -AT-deficient (Fig. 5) and normal alveolar macrophages. The synergistic effect of HNP and neutrophil elastase was significantly increased over that seen with HNP alone and over the effects of neutrophil elastase alone in normal alveolar macrophages. The neutrophil elastase-HNP enhancement of LTB 4 production was fourfold greater in alveolar macrophages isolated from ␣ 1 -AT-deficient individuals than in normal alveolar macrophages. Because of high variability in cellular response within each group, the difference did not reach statistical significance. In contrast to the synergistic effect with regard to cellular LTB 4 production, less production of IL-8 resulted from the combination of neutrophil elastase and HNP than from either treatment alone (Fig. 5) .
Importantly, the addition of ␣ 1 -AT completely prevented HNP from increasing LTB 4 production by alveolar macrophages isolated from ␣ 1 -AT-deficient individuals (Fig. 5) and from control subjects (data not shown). This was also true for the combined effect of neutrophil elastase and HNP with regard to LTB 4 production. ␣ 1 -AT also blocked HNP-induced IL-8 production by normal and ␣ 1 -AT-deficient alveolar macrophages.
DISCUSSION
Antimicrobial peptides are a key component of the human innate host defense system. Those produced by neutrophils play an important role in microbial killing in the intracellular environment but also possess properties that are potentially harmful to host tissue when released extracellularly. In this study, we evaluated the role of HNP in chronic inflammatory lung disease associated with ␣ 1 -AT deficiency. We observed that this neutrophil product is significantly elevated in the lower respiratory tract of these patients and that its levels correlate with other markers of neutrophil-mediated inflammation. At concentrations approximating those measured in the lower respiratory tract of a small subset of ␣ 1 -AT-deficient individuals, HNP were found to be cytotoxic to alveolar macrophages in vitro. Perhaps more importantly, HNP stimulated the production of potent neutrophil chemoattractants by alveolar macrophages. These data provide novel evidence that HNP play a significant role in lung disease associated with ␣ 1 -AT deficiency, a finding with potential relevance to other neutrophil-mediated lung disease as well as inflammatory conditions in other organ systems characterized by neutrophil activation.
HNP are abundant in neutrophils and lack enzymatic activity. Their cationic and amphiphilic characteristics facilitate interactions with microbial surface structures, and their mechanism of action involves the formation of membrane pores that alter microbial membrane permeability and internal homeostasis (14) . Although the majority of this activity takes place in neutrophil vacuoles after phagocytosis, activated and deteriorating neutrophils represent a source of extracellular HNP. Because HNP production is constitutive and regulated only by the intrinsic maturation program of the cell (10), the accumulation of large numbers of activated neutrophils at the surface of the airway or other tissues can result in high local concentrations of HNP. Along with the significant elevation of HNP in the lower respiratory tract of individuals with ␣ 1 -AT deficiency, we noted a strong correlation of HNP levels with the burden of neutrophils and inflammatory markers, demonstrating that HNP measurement may prove to be a useful biomarker of disease progression and severity.
The cytotoxic potential of HNP was first noted in tumor cell targets (13) . Subsequent in vitro assays demonstrated that neutrophil granule extracts are cytotoxic to pulmonary epithelial cells and pulmonary fibroblasts in a dose-dependent manner and that the cytotoxicity of the granule extracts is specifically due to their HNP content (16) . Our study demonstrates that the cytotoxic potential of HNP extends to alveolar macrophages. However, in this group of 33 individuals with mild lung dysfunction, only 6 had HNP levels that induced alveolar macrophage cytotoxicity under the assay conditions. Because of the in vitro dose-dependent response of alveolar macrophages, the cytotoxic effects of HNP may play a greater role with regard to lung damage and host cell defense in patients with a higher burden of extracellular HNP in the lower airways. This requires further study, because the in vivo cytotoxic effects of HNP may be partially mitigated by ␣ 1 -AT and by the binding of highly cationic HNP to anionic molecules such as mucopolysaccharides and nucleic acids.
Although HNP levels measured in a minority of patients approached concentrations noted to cause alveolar macrophage cytotoxicity, at lower concentrations the primary effect of unbound HNP appears to be perpetuation of the inflammatory response. HNP may play a significant role in the maintenance of chronic inflammation, as evidenced by a dose-dependent relation between HNP and alveolar macrophage production of the potent chemoattractants LTB 4 and IL-8. Importantly, HNPstimulated IL-8 and LTB 4 release by alveolar macrophages was completely abrogated by the addition of ␣ 1 -AT to the culture supernatant. The presence of adequate local concentrations of ␣ 1 -AT may therefore be critical in controlling the harmful effects of extracellular HNP in an environment of activated neutrophils.
In addition to the inflammatory effects of HNP alone, we noted a significant synergistic effect between HNP and neutrophil elastase in the stimulation of alveolar macrophage LTB 4 production, an effect also reversed by the addition of ␣ 1 -AT. In contrast, the combination of HNP and neutrophil elastase resulted in lower levels of IL-8 production by alveolar macrophages than by control cells or HNP and neutrophil elastase alone, although the difference was not statistically significant. This finding is consistent with the finding of a previous study that reported inhibitory interactions between HNP and neutrophil elastase with respect to pulmonary epithelial cell production of IL-8 (22) . These contrasting observations between stimulation and inhibition of alveolar macrophage LTB 4 and IL-8 production, respectively, warrant further study, as do the in vivo implications of our findings as they relate to perpetuation of the inflammatory cycle in this disease.
Consistent with the findings of other investigators (11), we found that, in normal alveolar macrophages, neutrophil elastase alone significantly increased LTB 4 secretion. In contrast, we found that neutrophil elastase alone did not increase LTB 4 production in alveolar macrophages isolated from ␣ 1 -ATdeficient individuals. Neutrophil elastase is bound and internalized by alveolar macrophages via nonspecific low-affinity receptors (6, 15) . Although this was not the focus of the present investigation, our finding warrants further focus on differences that may exist between normal and ␣ 1 -AT-deficient alveolar macrophages with regard to surface receptor expression or subsequent activation of arachadonic acid pathways after neutrophil elastase endocytosis.
In summary, we have demonstrated that HNP are significantly elevated in the lower respiratory tract of ␣ 1 -AT-deficient individuals. At concentrations approximating those measured in this group of patients with mild lung disease, HNP exhibited cytotoxic but primarily inflammatory properties when incubated with alveolar macrophages, effects that were abrogated by the addition of ␣ 1 -AT. Neutrophils are normally in low abundance and are not activated in the lower respiratory tract. HNP appear to contribute to inflammation and tissue destruction in the lower respiratory tract of ␣ 1 -AT-deficient individuals by promotion of neutrophil accumulation as well as by direct injury of lung cells. It is anticipated that the in vitro findings regarding HNP effects are not specific to ␣ 1 -AT deficiency. In fact, the findings may be relevant to a number of lung diseases characterized by chronic neutrophil-mediated inflammation in which elevated levels of HNP have been reported, such as cystic fibrosis (21), pulmonary tuberculosis (2), and diffuse panbronchiolitis (3) . HNP are likely key components in the promotion and maintenance of chronic lung inflammation and may be useful markers of neutrophil burden and activation.
